Vertex Pharmaceuticals (VRTX) Consolidated Net Income (2016 - 2025)
Vertex Pharmaceuticals has reported Consolidated Net Income over the past 16 years, most recently at $1.2 billion for Q4 2025.
- Quarterly results put Consolidated Net Income at $1.2 billion for Q4 2025, up 30.46% from a year ago — trailing twelve months through Dec 2025 was $4.0 billion (up 838.09% YoY), and the annual figure for FY2025 was $4.0 billion, up 838.09%.
- Consolidated Net Income for Q4 2025 was $1.2 billion at Vertex Pharmaceuticals, up from $1.1 billion in the prior quarter.
- Over the last five years, Consolidated Net Income for VRTX hit a ceiling of $1.2 billion in Q4 2025 and a floor of -$3.6 billion in Q2 2024.
- Median Consolidated Net Income over the past 5 years was $882.4 million (2021), compared with a mean of $635.1 million.
- Biggest five-year swings in Consolidated Net Income: soared 1109.7% in 2022 and later plummeted 492.44% in 2024.
- Vertex Pharmaceuticals' Consolidated Net Income stood at $770.1 million in 2021, then grew by 6.34% to $818.9 million in 2022, then rose by 18.31% to $968.8 million in 2023, then fell by 5.76% to $913.0 million in 2024, then surged by 30.46% to $1.2 billion in 2025.
- The last three reported values for Consolidated Net Income were $1.2 billion (Q4 2025), $1.1 billion (Q3 2025), and $1.0 billion (Q2 2025) per Business Quant data.